Bris­tol My­ers Squibb, Ac­celeron rack up sec­ond OK for Re­blozyl, on­to block­buster sta­tus

Re­blozyl, the ane­mia drug Cel­gene paid a mod­est $25 mil­lion up­front to part­ner on 9 years ago, brought Bris­tol My­ers Squibb one of on­ly two new drug ap­provals in 2019. Mere­ly five months lat­er, it’s tak­ing home an­oth­er sup­ple­men­tal OK ex­pect­ed to cat­a­pult sales in­to block­buster ter­ri­to­ry.

The FDA has ap­proved Re­blozyl (lus­pa­ter­cept) as a treat­ment for ane­mia in a sub­set of adults with low­er-risk myelodys­plas­tic syn­dromes. Specif­i­cal­ly, it’s lim­it­ed to pa­tients who have failed an ery­thro­poiesis stim­u­lat­ing agent and re­quire 2 or more red blood cell units over 8 weeks. These MDS pa­tients are fur­ther char­ac­ter­ized by ring sider­ob­lasts, where iron ac­cu­mu­lates in the mi­to­chon­dria of red blood cells, ren­der­ing them dys­func­tion­al.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.